The authorisation comes three months after the MHRA approved Johnson & Johnson’s Lazcluze (lazertinib), which is also ...

Patritumab deruxtecan treatment did not improve suvival end points versus those treated with chemotherapy in EGFR+ ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech', 6990.HK) today announced that results from its ...

Helena Yu, MD, discusses the efficacy of zipalertinib for EGFR-mutant non–small cell lung cancer and the importance of ...

In a recent study, researchers have uncovered the biological trigger behind the dangerous immune-related adverse events (irAEs) that occur when the ...

In a recent study, researchers have uncovered the biological trigger behind the dangerous immune-related adverse events ...

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

Patients with stage II and IIIB non-small cell lung cancer (NSCLC) with an EGFR mutation had better outcomes when treated ...

Biocartis NV (“Biocartis”), an innovative molecular diagnostics company, is pleased to announce that its Idylla™ EGFR Mutation Test has received the European Union (EU) Technical Documentation ...

The MHRA has approved aumolertinib for adult patients with non-small cell lung cancer (NSCLC), following a groundbreaking ...

The use of tyrosine kinase inhibitors (TKIs) in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) has not produced the same durable clinical benefits ...